Malignant fibrous histiocytoma of the sinonasal tract

Wang, Cheng-Ping; Chang, Yih‐Leong; Ting, Lai Lei; Yang, Tsung‐Lin; Ko, Jen-Chung; Lou, Pei‐Jen

doi:10.1002/hed.20936

Cited by 35 publications

(38 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…32 Lagrange et al reported that most RIS was high grade, as observed in our study, in which 66% were grade 3. 33 Regarding RIS site, the proportion of sarcomas that arose from the maxillary sinus in the current study cohort (18.9%) was consistent with the data reported by Wang et al 17 RIS traditionally has been viewed as an aggressive tumor with a generally poor prognosis. The 3-year OS rate for patients with RIS in our series (32.4%) was within the lower end of the wide range reported previously (8%-60% at 5 years).…”

Section: Radiation-induced Sarcoma In Npc/xi Et Alsupporting

confidence: 90%

Radiation‐induced sarcoma in patients with nasopharyngeal carcinoma

Liu

Wang

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND:The increasing incidence of radiation-induced sarcoma (RIS) has become a significant problem that can limit long-term survival. The objective of the current study was to analyze the clinicopathologic characteristics, treatment outcomes, and prognostic factors of RIS after radiotherapy for nasopharyngeal carcinoma (NPC). METH-ODS: Institutional electronic medical records of patients with NPC who received definitive radiotherapy between February 1964 and 2003 were reviewed. Fifty-three patients who developed RIS and fulfilled the study criteria were included. RESULTS: The median follow-up after a diagnosis of RIS was 15.5 months (range, 0.4-90.3 months), and the median latency between radiotherapy for NPC and an RIS diagnosis was 9.3 years (range, 3.2-26.6 years). Fibrosarcoma was the most frequent histologic type observed, followed by osteosarcoma, and malignant fibrous histiocytoma. The 3-year overall survival (OS) rate for 49 patients who received treatment was 32.4%, and the median survival was 21.2 months (95% confidence interval, 8.7-33.8 months). The median OS was 41.3 months, 8.4 months, and 11 months for the complete resection group, the incomplete resection group, and the chemotherapy group, respectively (P<.0001). The only independent predictive factor that was associated with better OS was complete surgical resection. CONCLUSIONS: This retrospective study confirmed the rarity and poor prognosis of RIS in patients with NPC. Complete surgical resection was a significant prognostic factor for survival. The authors concluded that long-term follow-up is necessary for the early detection of RIS in patients with NPC. Cancer 2010;116:5479-86.

show abstract

Section: Radiation-induced Sarcoma In Npc/xi Et Alsupporting

confidence: 90%

Radiation‐induced sarcoma in patients with nasopharyngeal carcinoma

Liu

Wang

et al. 2010

Cancer

View full text Add to dashboard Cite

show abstract

“…The study periods spanned the 1990s and/or 2000s, and dated back to the 1980s for 9 studies (Hsieh et al, 2003;Campbell et al, 2004;Hsu et al, 2004;Dickinson et al, 2006;Wu et al, 2006;Kim et al, 2007;2008c;Huang et al, 2010;Han et al, 2011) and the 1970s for 1 study (Wang et al, 2009) (Table 1). The number of patients [minimum, 12 (Jun et al, 2010); maximum, 324 (Dickinson et al, 2006) was fewer than 50 in 17 of the 32 studies.…”

Section: Study and Patient Characteristicsmentioning

confidence: 99%

“…The number of patients [minimum, 12 (Jun et al, 2010); maximum, 324 (Dickinson et al, 2006) was fewer than 50 in 17 of the 32 studies. Only 13 studies specified whether STS was primary or recurrent [8 primary (Dickinson et al, 2006;Hui et al, 2006;Wu et al, 2006;An et al, 2007;Kim et al, 2008a;Ng and Tan, 2009;Wang et al, 2009;Liu et al, 2010); 5 primary or recurrent (Hsieh et al, 2003;Kiatisevi et al, 2006;Moncrieff et al, 2008;Miki et al, 2010;Cho et al, 2011)]. Patients had local disease in 15 studies (Choong et al, 2003;Campbell et al, 2004;Hsu et al, 2004;Dickinson et al, 2006;Hui et al, 2006;An et al, 2007;Kim et al, 2007;2008c;Pervaiz et al, 2008;Rudiger et al, 2009;Wang et al, 2009;Liu et al, 2010;Cho et al, 2011;Han et al, 2011), and local or metastatic disease in 7 studies (Wu et al, 2006;Chan et al, 2008;Moncrieff et al, 2008;Koh et al, 2009;Jun et al, 2010;Park et al, 2010;Lee et al, 2011).…”

Section: Study and Patient Characteristicsmentioning

confidence: 99%

“…Nearly all patients were treated with surgery: 100% in 5 studies and 86%, 92%, and 99% in the other 3 studies ( Table 2). The remaining patients were not treated with surgery because it was not indicated (Wang et al, 2009), the surgery was biopsy only , or distant metastases were detected during restaging studies (eg, magnetic resonance imaging of primary tumour site) done after preoperative radiotherapy (Hui et al, 2006). Only 5 patients from 2 studies had amputations (Table 2).…”

Section: Studies Of Primary Soft-tissue Sarcomamentioning

confidence: 99%

“…The mean/median follow-up time varied from 16 to 53 months (Table 2). Survival rates [OS or disease-specific survival (DSS); reported in 7 studies] differed and were lowest (25%; 5-year OS rate) for sinonasal pleomorphic sarcoma (100% high grade) (Wang et al, 2009) and highest (93%; 53-month OS rate) for extremity liposarcoma (11% high grade) (Ng and Tan, 2009). The rate of local recurrence and/or distant metastases varied from 15% to 52% (Table 2).…”

Section: Studies Of Primary Soft-tissue Sarcomamentioning

confidence: 99%

See 2 more Smart Citations

Soft-tissue Sarcomas in the Asia-Pacific Region: A Systematic Review

Ngan¹,

Wang²,

Porter³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Asian Pac J Cancer Prev, 14 (11), [6821][6822][6823][6824][6825][6826][6827][6828][6829][6830][6831][6832] Introduction Soft-tissue sarcomas (STS) are a heterogeneous group of rare tumours. More than 50 STS histotypes have been identified, with most having unique clinical, prognostic, and therapeutic features. Although less than 1% of all adult malignant tumours are STS (Fletcher et al., 2002a), their treatment and management is complex because many tumour-related (eg, histotype, site, size, depth, grade, primary vs recurrent) (Singer et al., 1994;2000;Pisters et al., 1996) and treatment-related (eg, surgical margins, use of adjuvant therapy) (Singer et al., 2000) factors influence patient outcomes. Because these factors are inherently variable and because STS is rare, the management of patients with STS is best undertaken by an experienced multidisciplinary team in specialist centres to minimise recurrence, maximise survival, and preserve functionality and quality of life (Ray-Coquard et al., 2004;Luis et al., 2010; National Comprehensive Cancer Network, 2012).The standard primary treatment for STS is surgical AbstractBackground: Soft-tissue sarcomas require tailored and multidisciplinary treatment and management. However, little is known about how sarcomas are treated and managed throughout the Asia-Pacific region. Materials and Methods: MEDLINE was systematically searched using prespecified criteria. Publications (previous 10 years) that reported tumour characteristics, treatment patterns, survival outcomes, and/or safety outcomes of patients with soft-tissue sarcoma were selected. Exclusion criteria were studies of patients <18 years of age; ≤10 patients; countries other than Australia, Hong Kong, Indonesia, Korea, Malaysia, New Zealand, Philippines, Singapore, Taiwan, or Thailand; >20% benign tumours; sarcomas located in bones or joints; gastrointestinal stromal tumour; Kaposi's sarcoma; or not reporting relevant outcomes. Results: Of the 1,822 publications retrieved, 35 (32 studies) were included. Nearly all patients (98%, 1,992/2,024; 31 studies) were treated with surgery, and more studies used adjuvant radiotherapy than chemotherapy (24 vs 17 studies). Survival outcomes and recurrence rates varied among the studies because of the different histotypes, sites, and disease stages assessed. Only 5 studies reported safety findings. Conclusions: These findings highlight the lack of specific data available about soft-tissue sarcomas in the Asia-Pacific region. Better efforts to understand how the sarcoma is managed and treated will help improve patient outcomes in the region.

show abstract